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Executive Summary 
In November of 2008, the Global Fund to Fight HIV/AIDS, TB and Malaria announced that it would 
administer the first phase of an ambitious scheme to increase the availability of effective treatment 
for malaria, the Affordable Medicines Facility-malaria (AMFm).  Artemisinin-based combination 
therapies (ACTs) are highly effective, but remain prohibitively expensive for those who are most 
vulnerable to malaria infection.1  The AMFm aims to significantly reduce the price of ACTs by offering 
a co-payment for ACTs purchased by eligible buyers at the top of the supply chain. 
Recognizing that the public and private sectors are important sources of antimalarials in most 
endemic countries, both public and private sector buyers will be entitled to purchase subsidised 
ACTs.  The involvement of the private sector is an innovative element of AMFm, as many countries 
already have experience distributing ACTs in the public sector.  To ensure that subsidised ACTs reach 
patients at the lowest possible cost, it is necessary to gain a better understanding of the private 
sector supply chains for antimalarials in each country participating in the AMFm. 
The objective of the rapid supply chain survey was therefore to assist Nigeria, which is one of the 11 
countries invited to apply to the first phase of the AMFm, in the development of an effective 
implementation plan by providing an understanding of the current supply chain for antimalarials, 
and the way in which subsidised ACTs are likely to travel through this chain to reach patients.  This 
report presents the findings of a series of semi-structured interviews conducted with government 
officials and private suppliers of malaria treatment operating at the various levels of the chain.  
Supplemental sections include brief discussions on the Nigerian drug monitoring system, on the 
proposed tax exemption for subsidised ACTs under the AMFm, and also on the private sector 
capacity to repackage and re-label imported subsidised ACTs. In addition, data from the December 
2008 report on the first round of the ACTwatch Outlet Survey in Nigeria were used to estimate key 
variables, such as antimalarial market shares. 
In 2008, over 100 Nigerian manufacturers were registered to produce an antimalarial, while 10 of 
these were registered to produce an ACT product.  There were also 286 registered drug importers in 
Nigeria in 2008; however, there was insufficient data to determine how many of these businesses 
were importing antimalarials.  In terms of drug distribution and wholesaling, there were 616 
businesses licensed to do so in 2008; although it is widely accepted that unlicensed wholesalers play 
a very significant role in drug distribution at this level of the supply chain.  In terms of retailing and 
dispensing, the December 2008 ACTwatch Outlet Survey revealed that the most common source of 
antimalarials were Proprietary Patent Medicine Vendors (68%), followed by public (13%) then 
private (10%) health facilities.  Registered pharmacies, which numbered 1526 in 2008, were the least 
common formal source of antimalarials at 9%. 
Manufacturers and importers of antimalarials are concentrated mainly in the South-West region of 
the country in and around Lagos State, and to a lesser degree in Onitsha, Anambra State; while 
antimalarial wholesaling activity is typically concentrated within commercial hubs at the regional or 
state level, with notable pharmaceutical markets located in Kano, Aba and Ibadan (in addition to 
Lagos and Onitsha). 
                                                            
1 Nicholas White, “Malaria – Time to Act,” The New England Journal of Medicine. 355 (2006): 1956-1957.  
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Distribution practices vary, but are well established.  The use of vertically integrated distribution 
infrastructure and third-party logistics service providers is common among manufacturers and 
importers to achieve wide geographic coverage of their products.  This is enhanced through the 
pervasive use of sales representatives deployed, not only for product detailing, but also for order 
taking and delivery.  Authorised distributorship arrangements between top-level suppliers and 
wholesalers, which use a variety of incentives to increase product volume flowing through the 
supply chain, are also a prominent feature of distribution practices. 
Price mark-ups among manufacturers were reported to be between 15 and 40%, while importers 
indicated that their mark-ups depended on the costs of product and importation, exchange rate and 
competition.  Reported wholesaler mark-ups ranged from 1-15%, while those among retail 
pharmacies were estimated to be between 20% and 30%.  Credit facilities may be offered, but were 
reported to be less available at lower levels of the supply chain. 
The antimalarial product market in Nigeria is very diverse and includes 177 registered ACT products.  
The December 2008 ACTwatch Outlet Survey also showed that, in terms of volumes, the product 
market continues to be dominated by non-artemisinin therapies such as chloroquine and 
sulphadoxine pyrimethamine (SP), accounting for approximately 83% of the total number of adult 
treatment courses sold or dispensed, followed by artemisinin monotherapies (approximately 10% of 
the total volume).  On the whole, ACTs constituted approximately 6% of the total volume of adult 
antimalarial treatment courses dispensed.  This pattern of volumes was common across all types of 
antimalarial source, including public health facilities; although PPMVs appear to be a major driver 
behind the dispensing of non-artemisinin therapies, as they are the source for more than 60% of all 
antimalarials dispensed, of which more than 90% are of this type. 
When asked about the proposed AMFm mechanism, respondents generally reacted positively and 
agreed that this initiative could help to improve access to effective treatment for malaria.  They 
were also asked about any existing or potential barriers to the widespread distribution of ACTs in the 
private sector and identified a number of supply- and demand-side factors.  These included leakage 
of products to the informal sector, unpredictable top-level availability of product, poor acceptance 
of ACTs among consumers, opposition to the AMFm from local manufacturers of antimalarials, the 
role of PPMVs in improving accessibility to ACTs, and geographical accessibility of ACTs.  
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1. Context 
In November 2008, the Global Fund to Fight AIDS, Tuberculosis and Malaria launched the first phase 
of a new global subsidy on ACTs, known as the Affordable Medicines Facility-malaria (AMFm). The 
primary objectives of the AMFm are to make ACTs available and affordable to all patients through 
both the public and private sectors, and to delay the onset of artemisinin resistance by displacing 
artemisinin monotherapies from the market. 
Through a co-payment applied at the manufacturer level, the AMFm will enable public and private 
(both for profit and not-for-profit) suppliers in approved countries to purchase high-quality ACTs at a 
fraction of current prices.  As a result, it is expected that ACTs will be sold through private shops at a 
similar price to that of older and less effective drugs, thereby dramatically increasing patients’ access 
to ACTs.  The AMFm has been designed to ensure that first-line buyers, who operate at the top of 
the supply chain and are the first point of entry for drugs into the country, maintain any pre-existing 
purchasing relationships with manufacturers, and to minimise disruption to the operation of the 
supply chain.  Gaining a comprehensive understanding of public and private sector ACT distribution 
channels is therefore needed to ensure successful implementation of the AMFm, and ultimately 
maximise ACT access in each country. 
Nigeria is one of the 11 countries eligible to apply for the first phase of the AMFm that will operate 
for 18 months.  The AMFm country application form requests a description of the current supply 
chain for antimalarials across public and private sectors.  The description will serve as a key input 
into the selection and design of supporting interventions to ensure safe and effective distribution of 
subsidised ACTs under the AMFm. 
This report presents the findings of a rapid assessment of the private sector supply chain for 
antimalarials in Nigeria.  It seeks to identify the strengths and weaknesses of Nigeria’s supply chain, 
and describe how the private sector would respond to subsidised ACTs. The results of the rapid 
analysis are presented in several sections. First, the report describes the structure of the private 
sector supply chain for antimalarials in Nigeria, including a description of the business practices of 
key actors along the distribution chain.  Second, it identifies potential barriers that could inhibit the 
distribution of subsidised ACTs in the private sector.  Three supplemental sections include brief 
discussions on the Nigerian drug monitoring system, the proposed tax exemption for subsidised 
ACTs under the AMFm, and the private sector capacity to repackage and re-label imported 
subsidised ACTs. 
This assessment was undertaken within the broader set of activities of ACTwatch, a collaboration 
between Population Services International (PSI) and the London School of Hygiene & Tropical 
Medicine (LSHTM), which aims to provide and promote evidence and recommendations for policy 
makers on methods to increase availability and decrease the consumer price of quality assured 
artemisinin-based combination therapies through the private sector.  ACTwatch involves 3 main data 
collection activities: national level household and outlet surveys, both led by PSI; and a supply chain 
analysis which is led by LSHTM.   The analysis presented below draws on data collected in the first 
round of the Outlet Survey, and on the sampling methods and data collection instruments 
developed for the supply chain analysis.   
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2. Methods 
The rapid analysis of the private sector antimalarial supply chain in Nigeria used a mix of qualitative 
and quantitative methods. 
First, primary data were collected during 24 semi-structured qualitative interviews with stakeholders 
operating at different levels of the supply chain.  Of the 24 interviews, 7 were conducted with key 
informants from governmental, non-governmental and private sector organisations that play an 
important role in the supply chain (Table 1).  Key informants were asked questions about the overall 
supply chain for antimalarials in Nigeria; their perceptions of the effectiveness of regulations and 
other factors affecting the price and availability of antimalarials; and their view on the impact of the 
AMFm on the market for antimalarials in Nigeria. 
Table 1: Interviews with Government, NGOs and Private Sector Key Informants 
Organisation Type 
Society for Family Health NGO 
Pharmaceutical Manufacturers Group of the Manufacturers Association of 
Nigeria (PMG-MAN) 
Private 
Pharmacists Council of Nigeria – Headquarters Government 
National Malaria Control Programme Government 
Pharmacists Council of Nigeria – Enugu Government 
National Agency for Food and Drug Administration and Control (NAFDAC) Government 
Pharmacists Council of Nigeria – Kano Government 
 
The remaining 17 in-depth interviews were conducted with private sector wholesalers and retailers 
operating at all levels of the pharmaceutical supply chain (Table 2).  These respondents were asked 
questions about the structure of the market for antimalarials and their business practices, including 
their relationships with their suppliers and customers, stocking decisions, the level of competition 
and collusion in the market for antimalarials, and their perception of the appropriateness of 
regulations.  In addition, respondents were questioned about how their businesses and the market 
for antimalarials would respond to subsidised antimalarials through the AMFm. 
The interviewees were selected purposively through discussions with Society for Family Health (SFH) 
and Clinton Foundation (CF) staff working in Nigeria and were interviewed by a LSHTM researcher 
accompanied by a trained note taker using a prepared semi-structured interview guide. These 
primary data were supplemented with quantitative analysis of other data where possible.  In 
particular, data from the December 2008 report on the first round of the ACTwatch Outlet Survey in 
Nigeria were used to estimate key variables, such as antimalarial market shares. 
  
3 
 
Table 2: Interviews of Private Sector Supply Chain Businesses 
Business Type (Location) Identified by:2 
Importer (Lagos) ACTwatch Outlet Survey (OS) 
Manufacturer/Importer (Lagos) Society for Family Health (SFH) 
Manufacturer/Importer (Lagos) SFH, ACTwatch OS 
Wholesaler/Importer (Onitsha) SFH 
Wholesaler (Abuja) SFH 
Wholesaler (Abuja) SFH, ACTwatch OS 
Wholesaler (Abuja) SFH, ACTwatch OS 
Wholesaler (Enugu) SFH 
Wholesaler (Enugu) SFH 
Wholesaler (Kano) SFH 
Wholesaler (Kano) SFH 
Wholesaler (Kano) SFH 
Wholesaler (Kano) SFH 
Wholesaler (Lagos) SFH 
Wholesaler (Onitsha) SFH, ACTwatch OS 
Wholesaler/Retailer (Enugu) SFH 
Wholesaler/Retailer (Kano) SFH 
3. Antimalarials in the private sector in Nigeria 
3.1. The structure of the antimalarial supply chain 
A simplified schematic that describes the flow of antimalarials through the private commercial 
sector supply chain in Nigeria is provided in Appendix 1. 
 
Several pieces of Nigerian legislation and related regulations define how pharmaceuticals should be 
distributed from wholesalers to the private sector outlets located at the bottom of the chain. The 
solid arrows in Appendix 1 demarcate the distribution relationships permitted by legislative texts.  
Evidence suggests that these regulations are not adhered to in practice.  The alternating dash-and-
dotted arrows in Appendix 1 show the unauthorised distribution relationships identified during the 
rapid analysis.  Respondents strongly believe that Nigeria has a large informal private sector that 
plays a significant role in the distribution of medicines.  In addition, pharmaceuticals flow between 
the private and public sectors at different points along the supply chain; these flows are represented 
in the diagram with the dashed line. 
3.1.1. The sources of antimalarials in the private sector 
Antimalarial products sold to private sector wholesalers are procured from domestic manufacturers 
or from international manufacturers by private sector importers.  Local manufacturers may also 
import antimalarial products to complement domestically manufactured product lines. 
                                                            
2 Businesses interviewed for the rapid survey were identified either as suppliers of antimalarial retail outlets 
surveyed for the first round of the ACTwatch Outlet Survey (OS) in December 2008, or selected from a list of 
antimalarial wholesalers operating in the study area recommended by Society for Family Health (SFH) product 
detailers.  This latter strategy was used in order to reach the target number of interviews in the constrained 
period of data collection. 
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All antimalarial products must be registered by the National Agency for Food and Drug 
Administration and Control (NAFDAC) before they may be either manufactured in or imported into 
Nigeria.  In addition, pharmaceutical manufacturers and importers must be appropriately registered 
with the Pharmacists Council of Nigeria (see next section).  The headquarters of most drug 
manufacturers and importers are located in and around Lagos State and Onitsha, Anambra State.  In 
2008, there were 140 drug manufacturers registered with the Pharmacy Council of Nigeria (PCN), 
the government agency responsible for the regulation of pharmaceutical related activities, and 286 
drug importers.  Among the local manufacturers, over 100 of these are registered to produce an 
antimalarial medication, while 10 are registered to produce ACTs.  Imported ACTs come 
predominately from India, China, Western Europe, but also from other countries including Morocco, 
Senegal, Vietnam and Israel3. 
Several multinational pharmaceutical manufacturers have local subsidiaries that import their 
antimalarial products (e.g. Ipca Laboratories Ltd (India), Sanofi-Aventis (Morocco), Novartis (China, 
USA)), while other foreign manufacturers may deal with one or more local importers.4  However, 
while importers are free to change their suppliers, respondents indicated that it is common practice 
for importers to act as sole agents for products manufactured outside of Nigeria.  This tendency to 
enter into exclusivity agreements is fostered by the stringency of the registration requirements (i.e. 
foreign manufacturers must be certified by NAFDAC prior to supplying drugs for import which can be 
a lengthy process), the amount of time that it takes to develop a relationship with the supplier, and 
the amount of investment that goes into developing the local market for the imported product.  
Rather than changing suppliers, respondents indicated that they purchase from multiple suppliers, 
which allows importers to offer greater product variety to their customers. 
The large antimalarial importers interviewed order from their suppliers 3-6 times per year.  The 
quantities procured depend primarily on sales trends, but other factors taken into consideration 
include levels of remaining stock from previous consignments, knowledge of upcoming large 
customer orders or tenders (often from government), and changes in policy and/or 
recommendations.5,6  They indicated that shipments of orders usually take 4-6 weeks to arrive but 
can take longer, often due to problems with product availability and clearance at the port of entry.  
According to one respondent, the cost of freight is built into the product cost; however they bear the 
cost of transporting the goods from the port to their warehouse.  Clearance tax of 2-3% is also paid. 
For both manufacturer and importers, promotion is a key aspect of their business.  Teams of sales 
representatives and product detailers are based across the country and frequently visit customers to 
promote products, generate demand amongst prescribers, and to take and deliver orders.  As such, 
                                                            
3 The product registries provided by NAFDAC are incomplete and these numbers are approximations. 
4 Also derived from incomplete NAFDAC product registries, these examples are drawn from the list of foreign 
manufacturers that produce a WHO prequalified ACT who export any antimalarial product to Nigeria; for other 
WHO prequalified manufacturers, Cipla Ltd deals with one local importer, Evans Medical PLC; while Guilin 
Pharmaceutical Co. Ltd. deals with several local importers, including Asian Tiger Pharma Co., Chez Pharma Nig. 
Ltd. and Philips Pharmaceuticals Ltd. 
5 Both importers and manufacturers described how changing the malaria 1st line treatment policy to ACTs 
impacted the sales volumes of their antimalarial products, noting that market share of ACTs continues to grow. 
6 Local manufacturers reported that 70-75% of current antimalarial sales revenues were from non-artemisinin 
therapies (chloroquine and SP in particular); although the demand for ACTs is increasing and they predicted 
that ACTs could take up to 70% of antimalarial market share in as little as 6 months. 
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it is common for these staff to be provided with vehicles.  One manufacturer respondent indicated 
that they are actively involved in a programme for training PPMVs.  Bonuses (e.g. buy 10, get 1 free) 
and gifts (e.g. small appliances, promotional items) may be offered to customers; while discounts of 
2-5% may be offered to wholesale customers who qualify as ‘authorised distributors’ (see next 
section for description).  Discounts may also be offered to customers paying in cash.  
Price mark-ups among domestic manufacturers range from 15-40%, while the mark-up of importers 
was said to be dependent on the costs of products and importing, exchange rate and competition in 
market.  Credit facilities with terms ranging from 7-45 days may be offered to those wholesale 
customers who qualify as ‘authorised distributors’.  
3.1.2. The wholesaling of antimalarials in the private sector 
In order to manufacture, distribute, or retail pharmaceuticals, businesses must be registered with 
the PCN.  While it is not mandatory for manufacturers, importers, authorised distributors, or 
wholesalers that the business be owned by a licensed pharmacist, a pharmacist must be named as 
the superintendent pharmacist as part of the application.  Retail pharmacies, however, must list a 
registered pharmacist as at least one of the owners.  As a pharmacist may be associated with one 
business only, most pharmacists interviewed argued that this limitation dangerously restricts access 
of the population to good pharmaceutical care.  Also by the end of 2008, there were only 13,922 
licensed pharmacists in Nigeria (approximately 10,900 people/pharmacist7); so this limitation of 
practice is considered to be the largest barrier for new entrants to the market.  Apart from the 
pharmacist requirement, respondents for all types of business viewed the remaining requirements 
as reasonable and did not perceive them to be difficult for new businesses to achieve.  Proprietary 
Patent Medicine Vendors (PPMVs), on the other hand, are not required to have a pharmacist 
attached to the business.  Fees for initial PCN registration and renewal are given in Table 3. 
Table 3: Fees for initial PCN registration and renewal 
Registration Category Registration Fee (NGN)8 Renewal Fee (NGN) 
Manufacturer (2+ product lines9) 200,000 100,000 
Manufacturer (1 product line) 100,000 50,000 
Manufacturer (single product) 40,000 20,000 
Importers 100,000 50,000 
Authorised Distributors 80,000 40,000 
Wholesalers 50,000 25,000 
Retail Pharmacies 5,000  3,000 
PPMVs 2,000 1,000 
 
 
                                                            
7 Based on projected Nigerian population for 2008; Population Division of the Department of Economic and 
Social Affairs of the United Nations Secretariat. (2008) World Population Prospects: The 2008 Revision 
8 The avg. exchange rate in June 2009 (the month of data collection) was 1 US dollar to 149.39 Nigerian Naira 
9 A product line is a group of products marketed by a business sharing common active pharmaceutical 
ingredients that are sold in various strengths or dosage forms (e.g. Coartem 20/120 tablets is one product, but 
with Coartem-D dispersable tablets, they constitute a product line) 
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Once the imported or locally manufactured drugs have been cleared for release by NAFDAC, they 
move down the supply chain to end up in a variety of private sector drug outlets, including retail 
pharmacies, private hospitals and clinics, and PPMVs through two main channels: 
a) Series of depots specifically engaged in the warehousing and distribution of consumer products.  
These depots may be owned by a single enterprise also engaged in either drug manufacturing or 
importing, thus constituting a vertically integrated supply chain; but more commonly, these 
depots are owned by separate private enterprises that specialise in logistics and offer 
warehousing and distribution as a service for a wide range of products, including drugs (e.g. MDS 
Logistics10).  Manufacturers and importers will typically have one central warehouse where 
manufactured goods or received consignments will be stored prior to distributing to regional 
depots.  For those using a third party logistics company, transportation from port to central 
depot to regional depot may be included in the contracted service.  Both the central and 
regional depots are often used as warehouses from where their sales representatives who detail 
in the region may pick and fill orders that they themselves generate.  In other cases, wholesale 
customers may come to the depot to collect orders that they have placed by telephone.  As the 
number and distribution of these depots continues to increase, it is becoming more common for 
importers and manufacturers to sell directly to larger outlets (such as retail pharmacies and 
private health facilities), bypassing wholesalers. 
 
b) Private stand-alone wholesalers that purchase products directly from manufacturers and/or 
importers who then in turn sell to other wholesalers or drug outlets.  Many private wholesalers 
aspire to enter into ‘authorised distributorship’ agreements with their supplier.  These non-
exclusive agreements may only give these wholesalers the right to purchase directly from the 
manufacturer or importer (with the product often coming from the above depots); but more 
attractively, these agreements often allow wholesalers access to preferred pricing, discounts, 
credit facilities, and promotions.11  In all locations visited during the rapid supply chain analysis, 
suppliers had multiple authorised distributors.  In order to qualify for this preferred status, 
wholesale businesses may have to demonstrate a certain ability to reach and maintain specified 
sales targets, an ability to regularly settle accounts, and a capacity for storage and distribution.  
In order to access the benefits of these distributorship agreements, several interviewees 
revealed that competing wholesalers may even agree to pool their purchases to ensure that one 
of them might qualify.  Authorised distributors may also act as regional depots for suppliers who 
often attach sales/marketing representatives that detail prescribers to generate 
prescriptions/demand.  Under some agreements, orders that arise from these marketing 
activities will then be picked from the wholesaler’s inventories, thus contributing to their overall 
sales. 
 
                                                            
10 MDS Logistics is the largest third party logistics company in Nigeria providing logistics and ancillary services 
to manufacturers, wholesale distributors and importers.  They maintain a network of 47 distribution centers in 
31 states of Nigeria and over 200 warehouses. 
11 Wholesalers who are not authorised distributors may still be able to purchase from suppliers; however they 
may not be offered discounts, credit, or other benefits enjoyed by those customers who do qualify. 
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In 2008, there were 616 businesses licensed to distribute and wholesale pharmaceuticals in Nigeria.  
Apart from Lagos and Onitsha, other important regional wholesale drug markets are in Kano, Aba, 
and Ibadan.  Wholesalers’ choice of supplier is largely dependent on customer demand as suppliers 
are often associated with particular products.  However, there is also a great deal of value placed on 
offering customers a variety of product choice, so it is common for wholesalers to procure from 
many different suppliers.  To a lesser degree, wholesalers may purchase from a new supplier 
depending on product price.  As for determining purchase volumes, these decisions are based on 
considering monthly sales and also the time of year to account for the seasonality of malaria 
transmission.  Most orders are placed directly to manufacturers and importers through their sales 
representatives or via telephone, and these orders may be delivered (directly by sales 
representatives, waybilled12 or couriered) or picked up directly from the depot.  Orders are placed as 
required (as often as once a week), and lead times range from a few hours to one week.  In terms of 
financing, suppliers often require that orders be pre-paid or paid cash on delivery.  This was cited by 
many wholesalers interviewed as a barrier to increasing sales volumes as stock purchase size is often 
constrained by cash flow and limited access to credit. In some instances, particularly for authorised 
distributors, credit ranging from 7-45 days may be offered by the supplier. 
Distribution practices from the wholesale to retail level vary considerably, which ultimately 
determines the extent of wholesaler geographic coverage.  Some wholesalers focus much of their 
business within the state where they are located with some customers located in adjacent states, 
while others choose to actively seek out customers from a wide range of states.  While all 
wholesalers prefer to serve their customers directly on their premises, many also deliver using a 
variety of means (their own vehicles, waybilling and courier services), sometimes employing sales 
representatives themselves to both take orders and deliver.  As there is no price regulation of 
pharmaceutical products in Nigeria, price mark-ups vary considerably from 1-3%, to 5-10% for those 
wholesalers that deliver extensively, up to 15% if there is product scarcity.  Other factors that 
influence pricing decisions include competition, volume of customer purchase, product expiration 
date, and amount of discount received from the supplier. One respondent indicated that intense 
price competition allows for horizontal trade among wholesalers without significant impact on retail 
prices. Wholesalers may also offer credit terms of 1-3 weeks to their customers, particularly if the 
wholesaler has received credit from their suppliers.   
 
 
                                                            
12 In this common method of delivery, orders placed by customers typically in person or by telephone are 
packed by the supplier and transported via mass transit operators (e.g. bus lines) to regional transport hubs, 
such as bus or taxi parks in commercial centres, from where the customer will then retrieve their packaged 
order.  The cost of this delivery is typically borne by the customer who pays the fee to the transport operator 
upon retrieval of the package; however, some suppliers do offer this as delivery method as a service included 
in the price of the purchased goods. 
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3.1.3. The distribution of antimalarials to patients & the informal sector 
Patients in Nigeria access treatment for malaria in a diverse range of outlets in the public and private 
sectors.  Data from the ACTwatch Outlet Survey13 conducted by SFH in December 2008 showed that 
PPMVs (both registered and unregistered) were the most commonly encountered provider of 
antimalarials in Nigeria and accounted for 68% of all providers (Figure 1), while public and private 
health facilities and registered pharmacies each accounted for about a tenth of all providers.14  Note 
that certain types of informal outlets, particularly mobile vendors and hawkers, are not included in 
these estimates, although anecdotal evidence suggests that they may be common. 
There were 1526 retail pharmacies registered in 2008.  Pharmacies and private health facilities are 
located mainly in urban areas, while PPMVs, although prevalent in urban areas, are typically the 
most common and accessible medicines outlet in rural areas.  In 2006, there were a total of 13,903 
PPMVs registered with the PCN and this number is likely to have increased substantially since then.  
In addition, there are many PPMVs not registered with PCN.  As an indication of total numbers, 
scaling up data from the December 2008 ACTwatch Outlet Survey gives an estimated total of 43,000 
PPMVs across Nigeria.15,16 
 
Retail pharmacies and private health clinics typically procure drugs from wholesalers or directly from 
the manufacturer/importer through a sales representative or detailer.  Very large private health 
facilities may procure through a tendering process.  Some wholesalers reported to have PPMVs 
among their customers; however some respondents indicated that PPMVs may be more likely to 
purchase their supplies from unregistered drug wholesalers commonly found in central markets.  
These kinds of markets, which are the typical commercial centres selling a wide variety of consumer 
goods, are found in virtually all cities and towns across Nigeria.  Among wholesale respondents who 
also engage in retail activities, mark-ups were estimated to be in the range of 20-30%; and while 
interviewees were unsure, PPMV mark-ups were expected to be similar, if not higher. 
 
                                                            
13 “A total of 607 outlets were sampled (by strata: Lower North, N=155; South/Southeast, N=153; Upper North, 
N=112; Southwest, N=187).  24 providers refused to be interviewed; 13 outlets were permanently closed; 50 
outlets were closed at the time of the visits (up to three visits before exclusion); and in 52 outlets, providers 
were not available for interview at the time of data collection.  These outlets were excluded from the analysis.  
Overall, 468 providers agreed to participate in the ACTwatch outlet survey.  Of these, all 468 outlets stocked 
antimalarials at any point in the three months prior to the interview, and 444 outlets stocked antimalarials at 
the time of the interview.” ACTwatch Group. (2009) Outlet Survey Report (Baseline), Nigeria 2008. 
www.actwatch.info/results 
14 ACTwatch Group. (2009) Outlet Survey Report (Baseline), Nigeria 2008. www.actwatch.info/results 
15 ibid. 
16 Rough estimation that used total number of PPMVs found to be selling antimalarials in the 76 sub-districts 
surveyed during round 1 of ACTwatch Outlet Survey in December 2008, scaled up to all endemic areas using a 
multiplier based on population estimates from Nigeria census data.  See appendix 2. 
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Figure 1: Retail providers of antimalarials in endemic areas, by type and estimated % of total retail providers (N=462)* 
 
Source: ACTwatch Group. (2009) Outlet Survey Report (Baseline), Nigeria 2008. www.actwatch.info/results 
*Note that certain types of informal outlets, particularly mobile vendors and hawkers, are not included in these estimates, 
nor in those shown in other figures, as they were not surveyed during data collection for the first round of the ACTwatch 
Outlet Survey in December 2008, although anecdotal evidence suggests that they may be common. 
 
The informal market is believed to play a very significant role in the supply chain for antimalarials in 
Nigeria.  It consists of a wide range of facility types, including unregistered PPMVs, and non-
traditional medicines outlets such as hawkers/mobile vendors that may operate at transport hubs, 
supermarkets, community health extension workers, and Role Model Mothers (a type of volunteer 
community health worker).  However the most important type of informal market actor is the 
market trader that often engages in both drug retailing and wholesaling and can be commonly found 
in the central markets of cities and towns. It is believed that many of these market traders are 
registered as PPMVs with the PCN, but operate beyond the scope of their regulated activities.  
Almost all wholesaler respondents consider these market traders to be important competitors in the 
wholesale market for antimalarials.  Because of the pressure in the formal market to meet sales 
volume targets, it is believed that much of the inventory sold by informal market traders comes 
directly from manufacturers, importers and wholesalers themselves.  It is also widely accepted that a 
proportion of the total inventory across the entire private sector (i.e. both formal and informal) 
consists of smuggled genuine products (or ‘parallel imports’), counterfeits, and also drugs leaked 
from the public sector.  Respondents indicated that the informal market traders are attractive to 
many retailers, particularly PPMVs, because of the competitive prices and convenience (i.e. 
customers can find all the products they are looking for in one place).   
As indicated on the diagram in Appendix 1, the private sector supplies antimalarials to the public 
sector, typically through a tendering process but also via ad hoc small/emergency purchases.  There 
are two state-level Central Medical Stores (CMS) in Benue and Ekiti states that are now wholesaling 
to the private sector.  Interviewees from PCN indicated that this was a pilot programme that may be 
extended to include additional state CMSs. 
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3.2. Antimalarial products in the private sector 
There are currently more than 265 artemisinin-based antimalarial products registered with NAFDAC 
for distribution in Nigeria.  Of these, only 33 are manufactured in the country while the remainder  
are imported from mainly China, India and Western Europe.  More than half of these registered 
products are ACTs (177), of which 15 are manufactured in Nigeria.  A list of domestically 
manufactured artemisinin-based antimalarial products is included in Appendix 4. 
To estimate market shares of different antimalarial products, data on the recalled volumes the week 
preceding the survey from the first round of the ACTwatch Outlet Survey conducted by PSI and SFH 
in December 2008 were used to calculate adult equivalent treatment doses (AETD) for each 
antimalarial drug sold in tablet form only (see Appendix 3)17.  The categories of antimalarial type 
(WHO approved ACT, Non‐WHO approved ACT, Non‐artemisinin therapy, Artemisinin monotherapy) 
used for analysis were selected to best illustrate the potential impact of the AMFm, as only WHO 
approved ACTs will be eligible for the AMFm subsidy.18  Depending on the brand, the government-
recommended first line treatment, artemether lumefantrine, falls into either the WHO approved 
ACT or Non‐WHO approved ACT category. 
In terms of where antimalarials were dispensed, only 5% of all AETDs distributed or sold were 
provided through public health facilities (which include university and general hospitals, federal 
medical centres, primary health centres and community health extension workers), while the 
remaining 95% was sold through the private sector (Figure 2). 62% of all types of AETDs were 
provided through PPMVs, while Registered Pharmacies were the second largest source of 
antimalarials (28% of AETDs). 19  
The December 2008 ACTwatch Outlet Survey data also revealed that non-artemisinin therapies 
continue to dominate the volumes dispensed.  Of all AETDs sold or dispensed, 84.4% were non-
artemisinin therapies, while 9.2% were artemisinin monotherapies (Figure 3, rightmost bar labelled 
‘Total’).  This pattern was consistently observed across all outlet types (Figure 3), even among public 
health facilities where one would expect recommended treatment guidelines to be more strictly 
observed.  Also of note was that ACTs constituted less than 2% of the volume sold through PPMVs.20   
                                                            
17 The ACTwatch December 2008 Outlet Survey baseline report for Nigeria does not include pediatric 
formulations in the volumes and prices reported. 
18 The ACTwatch December 2008 Outlet Survey report for Nigeria presents four ACT categories throughout: 
First line treatment, WHO approved ACT, Nationally registered ACT, Non‐WHO/nationally registered ACT.  
Because first three categories are not mutually exclusive, for the purpose of the rapid assessment we have 
retained the category of WHO approved ACT, as well as a second category, non-WHO approved ACT. The 
category of non-WHO approved ACT estimates the volume of ACTs distributed in the past week that are not 
approved by the WHO, regardless if they are nationally registered or not. We calculated volume of non-WHO 
approved ACTs by adding the volume of Nationally registered ACTs to the volume of Non-WHO/nationally 
registered ACTs and subtracting the volume of WHO approved ACTs distributed, as they were reported in the 
ACTwatch baseline Outlet Survey Report. 
19 ACTwatch Group. (2009) Outlet Survey Report (Baseline), Nigeria 2008. www.actwatch.info/results 
20 ibid. 
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Figure 2: Total volume of all antimalarials sold or distributed in the past week by outlet type (n=18,548 AETDs) 
 
Source: ACTwatch Group. (2009) Outlet Survey Report (Baseline), Nigeria 2008. www.actwatch.info/results 
 
Source: ACTwatch Group. (2009) Outlet Survey Report (Baseline), Nigeria 2008. www.actwatch.info/results 
 
Looking more closely at the volumes of non-artemisinin therapies dispensed across outlet types 
(Figure 4), chloroquine and SP are the dominant antimalarials.  Sulphadoxine pyrimethamine 
accounts for as little as 54% of non-artemisinin AETDs dispensed within PPMVs to as high as 83% 
among registered pharmacies.  It is also worth noting that among PPMVs where 62% of all adult 
treatment courses of any kind are dispensed (Figure 2), 92% of what is dispensed consists of non-
artemisinin therapies; chloroquine and SP combined account for 99% of these volumes.21 
                                                            
21 ACTwatch Group. (2009) Outlet Survey Report (Baseline), Nigeria 2008. www.actwatch.info/results 
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Figure 3: Breakdown of total volume of antimalarials sold or distributed in the past week by antimalarial category and outlet type 
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Figure 4: Breakdown of non-artemisinin therapy volumes sold or distributed in the past week by product and outlet type 
 
The market share of the various outlet types also varies by antimalarial type.  Figure 5 shows the 
distribution of recalled sales volumes collected from round 1 of the ACTwatch Outlet Survey by 
antimalarial and outlet type.  Registered pharmacies account for the majority of ACTs distributed for 
both ACT categories.  With particular regard to the market share of WHO approved ACTs, over 90% 
of the AETDs dispensed were distributed through registered pharmacies with none of this 
medication being recorded as dispensed from public health facilities.22 
In contrast, the market for non-artemisinin therapies (particularly chloroquine and SP) is dominated 
by PPMVs, accounting for 67% of the recalled sales volumes of this type of antimalarial.  This is 
followed by registered pharmacies where 22% of the recalled sales volumes for non-artemisinin 
therapies were dispensed.  Artemisinin monotherapies were found to be sold predominantly in 
PPMVs and registered pharmacies with each accounting for approximately 40% of the volumes 
dispensed.23 
Figure 5: Market share of antimalarial sales volume by outlet type and treatment type 
 
Source: ACTwatch Group. (2009) Outlet Survey Report (Baseline), Nigeria 2008. www.actwatch.info/results 
                                                            
22 ACTwatch Group. (2009) Outlet Survey Report (Baseline), Nigeria 2008. www.actwatch.info/results 
23 ibid. 
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4. Barriers to widespread distribution of ACTs in the private sector 
Respondents generally reacted positively to the proposed AMFm mechanism and agreed that this 
initiative could help to improve access to effective treatment for malaria.  Both importers and 
wholesalers indicated a willingness to participate because it was an opportunity to help address an 
important health problem in Nigeria as well as to potentially improve overall sales, particularly since 
sales of all types of antimalarials reportedly constitute between 20-40% of total sales revenue. 
Experiences of subsidising ACTs in other countries provide indications of the potential impact on 
market share such a subsidy could have in Nigeria.  Preliminary results from the ACT Leaf 
programme in Uganda show that the subsidised product has achieved approximately 30% share of 
the market for malaria treatment24 after 6 months of operation, while in Tanzania, the Clinton 
Foundation subsidy pilot achieved nearly 50% market share in some of the studied areas after one 
year.25  Those wholesalers that stock the current recommended first line antimalarial, artemether 
lumefantrine, and Coartem in particular, indicated that they would be willing to increase their stocks 
once subsidised; and those that did not stock it were willing to do so under the AMFm.  In general, 
the wholesalers interviewed believed that significant substitution of older antimalarials (i.e. 
chloroquine and SP) could occur if the subsidised price was comparable to that of the older products 
and if supported by appropriate interventions; this substitution, however, will not be complete as 
familiarity with these older products will still generate some demand.  Respondents from different 
levels of the supply chain also predicted that this substitution would take time as consumers switch 
from their current preferred antimalarial to the subsidised antimalarial, giving businesses time to 
adjust their product lines and business model (e.g. marketing, distribution, etc.)  Respondents also 
predict that the level of substitution would be less among more expensive medicines due to 
consumer preference for premium priced products. 
Despite some reservations regarding availability of stock and supplier pricing, almost all respondents 
interviewed at the intermediate wholesale level (i.e. wholesalers who purchase from manufacturer 
or importer) believed that the increase in sales volume of the subsidised product both from 
substitution away from cheaper antimalarials and ACT market expansion would compensate for the 
decrease in absolute profit per pack sold so long as consumer demand is developed and maintained 
through appropriate product promotion.  To further guarantee the volumes necessary to maintain 
profit, several of those interviewed suggested limiting the number of participating wholesalers. 
In addition, interviewees identified several potential challenges that could inhibit the availability of 
ACTs in the private sector (which are discussed in further detail below):  
1) Leakage to the informal sector  
2) Top-level availability of subsidised product 
3) Poor acceptance of subsidised product among consumers 
4) Opposition from local manufacturers of antimalarials 
5) PPMVs and improving accessibility to subsidised product 
6) Geographical accessibility of subsidised product  
                                                            
24 From discussions with staff from Medicines for Malaria Ventures in April 2009 
25 Sabot OJ, et al. (2009).  Piloting the global subsidy: the impact of subsidised artemisinin-based combination 
therapies distributed through private drug shops in rural Tanzania. PLoS One. Sep 2;4(9):e6857. 
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4.1. Leakage to the informal sector 
This continues to be an immense challenge in Nigeria as the continuity of quality assurance 
mechanisms built into the regulation of the pharmaceutical supply chain (e.g. monitoring of storage 
conditions, product expiration, etc.) cannot be enforced, thus negatively impacting treatment 
outcomes.  It is widely believed that the informal sector is a very significant source of drugs for 
businesses at the outlet level, with much of their inventory originating from the formal sector.  
While respondents conceded that eliminating the informal sector was an unrealistic goal, they also 
indicated the unfeasibility of imposing regulation on the sector.  Instead, most respondents 
suggested that improved product tracking by a regulatory body from the point of manufacture to 
dispensing could help to prevent such leakage and ultimately improve end-user product quality.  
With the recent introduction of the PCN Drug Distribution Inspection Committee (DDIC), there 
appears to be greater commitment to ‘sanitising’ the drug distribution system in Nigeria in such a 
way, largely based on regular inspection of documentation throughout the supply chain, and some 
proposed reforms have already been pilot tested in three states, including Lagos.  However, it is 
widely recognised that PCN lacks the necessary funds and human resources to meet its current 
service standards, so it is unlikely that the DDIC will be able to implement the recommended reforms 
in time for introduction of the AMFm. 
Several wholesale respondents also attributed poor levels of regulatory compliance within the 
formal drug sector to the same funding and capacity constraints, but also to a perceived lack of 
power on the part of PCN to enforce regulations and impose penalties.  This situation could possibly 
be improved through more coordination between PCN and NAFDAC on monitoring and 
enforcement, and by establishing greater clarity and distinction on the mandated roles of the two 
government agencies.26 
Because the proposed 1st line buyers under the AMFm in Nigeria include SFH, several respondents 
suggested that 2nd line buyers could be selected among reputable wholesalers who have had 
previous dealings with SFH and whose superintendent pharmacist plays an active role in the running 
of the business.  This will guarantee revenue at the wholesale level by ensuring that retailing outlets 
do not bypass wholesalers while pharmacists, who have their license at stake, will ensure that 
subsidised ACTs are sold to duly registered outlets.  Many respondents indicated that if too many 
wholesalers were permitted to sell the subsidised product, it would become increasingly difficult to 
trace any leakages. 
Also to minimise the prevalence of counterfeits, supporting interventions to differentiate the 
subsidised product from fake products should be put in place, such as tamper-proof safety seals, 
distinct packaging, and promotion to increase awareness of where to purchase the subsidised 
product in the community. 
  
                                                            
26 Respondents from PCN also described how their shift toward a more participatory monitoring model (with 
more frequent informal visits) and away from a model more dependent on formal inspections has improved 
compliance overall and has been warmly received by private sector businesses. 
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4.2. Top-level availability of subsidised product 
Several respondents strongly felt that sustained regular availability of the subsidised product from 
manufacturers and importers will be crucial to avoid price speculation associated with scarcity.  They 
believed that poor availability would prevent the subsidised products from being sold at the target 
price.  This would have a negative impact on consumer confidence and would create a more 
lucrative environment for counterfeiting and leakage.  
4.3. Poor acceptance of subsidised product among consumers 
While respondents predict that many people will switch to the subsidised product once available, 
they were also adamant that there will still be a significant market for other antimalarials, such as 
the niche market for premium products.  Other reasons given for the poor acceptance of the 
subsidised product include the excessive pill burden of artemether lumefantrine and also the 
continuing popular support for the older antimalarials, such as chloroquine and SP even among 
pharmacists and medical doctors.  The December 2008 ACTwatch Outlet Survey results show that 
such non-artemisinin therapies, and particularly sulphadoxine pyrimethamine, are still the most 
commonly dispensed antimalarials across all outlet types, even in public health facilities.27 
In addition to the comparatively low price, the familiarity of these older products and past successful 
treatment experiences also drive the continued demand for chloroquine in particular.  Increased 
sensitisation about the treatment failure rates and the additional costs that could be faced due to 
treatment failure both among health professionals and the community could help to increase 
substitution toward subsidised ACTs away from chloroquine and SP.  As price setting in the private 
sector appears to be influenced in large part by product availability, perhaps banning of chloroquine 
and SP retailing (except for certain conditions such as malaria among sickle cell patients and IPT) 
could create product scarcity that would drive up prices and facilitate substitution toward subsidised 
ACTs.  Unpublished data from the ACTwatch Supply Chain Study indicates that this is being 
experienced in Uganda where such a ban has been imposed.  A ban could, however, push the 
wholesaling of chloroquine and SP further into the informal sector and make counterfeiting and 
smuggling of banned products more lucrative.  Additionally, while a ban on artemisinin 
monotherapies (AMTs) has not been imposed, one respondent indicated that NAFDAC has stopped 
registering new AMTs, and that upon expiry those AMTs already registered will not be renewed.  
Certificates of registration issued by NAFDAC are valid for a period of 5 years. 
4.4. Opposition from local manufacturers of antimalarials 
Because local manufacturers will not be able to access AMFm funds to subsidise their products, they 
will likely lose significant market share upon introduction of the AMFm.  This will be compounded by 
substitution away from locally manufactured AMTs and older medications, toward the subsidised 
ACT.  The manufacturers interviewed question the sustainability of the AMFm and criticised the lack 
of consideration given to developing pharmaceutical self-sufficiency in Nigeria.  These respondents 
urged that local manufacturers should be assigned a role under the AMFm, perhaps in distribution or 
                                                            
27 ACTwatch Group. (2009) Outlet Survey Report (Baseline), Nigeria 2008. www.actwatch.info/results 
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repackaging in the short-term or contracted local manufacturing of the subsidised product in the 
medium-term; otherwise they could pose a significant threat to the success of the subsidy.28 
4.5. PPMVs and improving accessibility to subsidised product 
Because PPMVs handle the majority of antimalarial volumes at the outlet level in Nigeria (most of 
which are not ACTs), all respondents recognised the importance of their participation in the AMFm.  
PPMVs have a reputation for providing poor pharmaceutical care to consumers, as they often 
dispense medicines that they are not permitted to sell (e.g. injectables and antibiotics), diagnose 
without proper training and operate without proper registration. As a result, many wholesaler 
respondents (almost all of whom were pharmacists by training) indicated that they were reluctant to 
engage them as customers.29  Furthermore, they believe that PPMVs are more likely to purchase 
their supplies from the informal sector.  To ensure that PPMVs can more readily procure supplies 
through the formal sector, relations between pharmacists and PPMV operators must improve, 
perhaps through redoubled efforts to register PPMVs and their premises with PCN, and to train 
PPMV operators on dispensing, storage, diagnosis and stock management.  
Also as the greatest potential for substitution from older therapies to ACTs rests among PPMVs who 
are often not targeted by sales representatives for detailing, several respondents suggested that 
more PPMVs could be included in the usual marketing and sales activities (including order taking and 
delivery) already being done by private sector distributors; however this would increase marketing 
expenses. 
4.6. Geographical accessibility of subsidised product 
Because sales volume targets are common and important features of authorised distributorship 
agreements between suppliers and wholesalers, discussions on incentives tended to focus more on 
how these could be used to improve distribution.  Most wholesalers indicated a willingness to do 
more deliveries and push ‘further into the grassroots’.  To do this, they requested help with costs 
associated with logistics (purchase and maintenance of vehicle, fuel, accommodation while in the 
field, per diems, etc.) and staffing.  Apart from direct cash incentives, they suggested easier access to 
credit facilities, and to low-interest and low-collateral loans.  Suggested non-financial incentives 
included guaranteed territory for distribution, better access to good warehousing facilities, and 
marketing assistance from suppliers (e.g. suppliers could distribute lists of authorised distributors 
through their network of sales representatives in the field).  Because the relationship between the 
supplier and authorised distributor is an important one to which many wholesalers aspire, perhaps 
this can be leveraged to include some socially responsible targets related to improving geographical 
coverage. 
                                                            
28 Respondents did not elaborate on specific threats, but emphasized that local manufacturers are powerful 
actors that could exhibit considerable influence as lobbyists and on drug distribution practices 
29 One pharmacist respondent indicated that they require all wholesale customers to produce evidence of 
current PCN registration prior to being served 
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5. Discussion on the national drug monitoring system 
5.1. Pharmacovigilance system in Nigeria 
The majority of pharmacovigilance data in Nigeria is generated via passive surveillance in health 
facilities.  First, primary evaluation of the potential event is done at the health facility.  In some 
facilities, there are committees tasked to review potential adverse events.  If deemed to be an 
adverse event, a NAFDAC adverse event reporting form (‘yellow form’) should be completed and 
forwarded to the NAFDAC Pharmacovigilance Centre with any necessary attachments.  These forms 
are provided to all health facilities free of charge.  The forms also have pre-paid postage, so that 
once completed, they can be dropped in the post for forwarding to NAFDAC. 
The NAFDAC Pharmacovigilance Centre has an expert committee that reviews these adverse events 
and determines if these reports should be forwarded to the WHO International Drug Monitoring 
Programme in Uppsala, Sweden.  The NAFDAC Pharmacovigilance Centre will also send a report to 
the owner/manufacturer of the product and decide which steps are to be taken (e.g. whether to 
recall the product, whether to have the manufacturer review the formulation or withdraw the 
product totally from circulation). 
This is the most formalised adverse events monitoring in the country and occurs at the facility level 
in the out-patient and in-patient settings.  Within the community, reporting of adverse events is 
dependent on the initiative of both the individual to report the event and on the provider of 
pharmaceutical care to probe their patient or customer for any potential adverse reactions during 
subsequent visits.  The same adverse event reporting forms are in theory available to health 
professionals from NAFDAC for this type of passive surveillance; though it is unclear how many 
reported adverse events are identified in this way.  One respondent indicated that NAFDAC is 
presently training health care workers at different levels of the health system, including Community 
Health Workers, on how to better identify and report adverse events.  This could also be reinforced 
through enhanced pre-service pharmacovigilance training for pharmacists or as continuing 
education, and discussion in professional newsletters, communiqués and circulars. 
In the private sector, drug manufacturers conduct ‘in-house’ adverse events monitoring.  
Manufacturers appear to have a variety of methods to identify potential adverse events: customer 
call centres, feedback from point of sales and prescribers, and through ad hoc surveys of customers 
(e.g. patients and/or outlets).  One manufacturer has standard reporting forms that are carried by 
field staff/sales representatives.  Potential adverse events are first investigated internally, primarily 
to determine if the product implicated is genuinely theirs.  Manufacturers typically employ a 
regulatory affairs manager or medical adviser who may then liaise with NAFDAC on the subject and 
determine appropriate action. 
The sharing of results from internal investigations among manufacturers with NAFDAC seems to be 
voluntary.  Therefore, less severe events which may not be deemed serious enough to communicate 
to NAFDAC will likely not contribute to national adverse events databases.  These events are also 
less likely to be picked up in the facility-based system as they typically will not present at health 
facilities. 
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It is unclear how similar in-house adverse event reporting forms of drug manufacturers are to the 
NAFDAC standardised form, or even if a basic set of common essential indicators are being collected.  
If this could be established, then data on adverse events from the parallel public and private 
pharmacovigilance systems could be more readily combined to provide a more complete national 
picture of the incidence of adverse events. 
The time required to complete and submit reporting forms in health facilities is also considered to be 
an important factor limiting the completeness of reporting.  One respondent suggested that perhaps 
the data requirements and the process of event reporting could be reviewed to see if this time 
burden can be reduced.  The effectiveness of training and its impact on the completeness of 
reporting could also be studied in order to optimise these inputs. 
It is, however, well known that self-treatment and advice from non-professionals is common for 
malaria treatment in Nigeria, which renders the predominantly facility and professional driven form 
of pharmacovigilance largely ineffective at the community level.  Outside of the health facility 
setting, these pre-paid reporting forms are still meant to be used but the collection of adverse event 
data is largely initiated through voluntary patient reporting.  And because most antimalarials will be 
consumed outside of health facilities, it is likely that only severe adverse events will be captured by 
the facility-based reporting system since these are most likely to present at a health facility.  Less 
severe adverse events will likely be under-reported.  Efforts to increase awareness within the 
community could be made to help individuals recognise potential adverse events (e.g. “if you 
recently took a medication and felt unwell, worse off, or failed to recover, you should…”), know who 
to speak to about the episode (e.g. speak to the person from whom you purchased the medicine, 
health professional at government health facility, etc.), and a very basic understanding of what 
information they should bring with them (e.g. original packaging, prescription, description of types 
and timing of signs and symptoms, etc.)  Better training of PPMV owners and dispensers to increase 
use of adverse events reporting forms could also improve reporting. 
5.2. Drug quality monitoring in Nigeria 
According to NAFDAC, drug quality is monitored at various levels of the supply chain.  Primarily, 
drugs are tested by NAFDAC at the point of entry (either at import for internationally manufactured 
products, or at the factory gate for locally made products) where they are sampled, tested and 
certified prior to being released for distribution within Nigeria. 
Once the products have entered into local distribution, NAFDAC also conducts routine sampling and 
testing of products at all levels of the supply chain (distribution, wholesale, retail and household) to 
support public health programmes.  In theory, this level of monitoring allows NAFDAC to identify 
where breakdowns in pharmaceutical management practices (e.g. poor storage conditions, lost 
records, etc.) may have occurred in the supply chain that lead to drug quality issues and to trace 
back to where in the supply chain these failures occurred, identify implicated products, isolate them 
and issue recalls as necessary.  Due to the limited scope of this rapid analysis, the implementation 
and effectiveness of such practices at ensuring drug quality could not be evaluated. 
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5.3. Antimalarial drug resistance monitoring in Nigeria 
According to the National Malaria Control Programme, data for drug resistance surveillance comes 
from routinely collected data as part of the National Health Management Information System 
(NHMIS), from 14 sentinel sites located throughout the six geopolitical zones of the country, and also 
ad hoc population level surveys.  For routinely collected data, reporting is monthly; however 
completeness and timeliness of reporting is often affected by the deficiency in capacity, inadequate 
resources, poor communication and transmission of data from health facilities at State and local 
government levels. 
As much of the treatment at the community level is delivered through private channels, many 
instances of treatment failure may not be picked up through the regular methods of data collection, 
underestimating the prevalence and rates of drug resistance.  Improvement in drug resistance 
monitoring at the community level could be achieved perhaps through interventions aimed at 
increasing private sector involvement in national drug monitoring activities.  
6. Discussion on the proposed tax exemption for subsidised ACTs 
For Nigeria, it has been proposed that NGOs experienced in international drug procurement and 
supply chain management, rather than private commercial sector drug importers, serve as the 1st 
line buyers of subsidised ACTs under the AMFm in order to take advantage of tax exemptions 
afforded these types of organisations under current legislation. 
Most respondents who were asked for their opinions on this arrangement responded positively, 
primarily because they expressed concern over the feasibility of meeting target price points at each 
stage of the supply chain: the 1st line buyer tax exemption provides more leeway to meet those 
targets while ensuring enough of a margin can be gained. 
Passing on of tax savings could also lead to additional profits for the 2nd line buyer which could be 
invested into improving distribution and geographic coverage.  Alternatively, the additional profits 
generated by the tax exemption could be used by the 1st line buyer to provide a greater range of 
incentives, both financial and non-financial, or to address some of the other potential challenges 
identified. 
7. Discussion on private sector capacity to repackage and relabel 
Certain respondents were also asked to comment on their capacity and willingness to either 
repackage or re-label imported subsidised ACTs.  Responses varied considerably. 
In general, the process of approval for repackaging a pharmaceutical product with NAFDAC is 
perceived to be straightforward as it is essentially the same as registering a finished product.  The 
business must pay the registration fee, submit a sample of the finished product and describe how 
the product will be sold and distributed.  NAFDAC may ask them to resubmit another sample once 
the packaging has been finalised.  NAFDAC may also then inspect the facilities, but this has not been 
the experience for all respondents. 
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Among respondents who do not locally manufacture antimalarials, most indicated that they did not 
currently repackage or re-label.  While they said that to do so would be feasible, they believe that it 
would be better for their suppliers to do the repackaging, preferably the manufacturer.  One 
respondent indicated that his operations were optimised to do only warehousing and distribution 
and that including repackaging and/or relabeling would require additional space, staff and 
equipment.   
Another respondent highlighted past experience with the introduction of SP for community-level 
distribution in the public sector.  At that time, the manufacturer of this particular SP was able to 
provide the product in special packaging in order to differentiate it from the identical product 
available in the private sector.  This respondent suggested this as an option for the AMFm in Nigeria. 
One large importer of antimalarials that does not currently repackage or re-label imported goods 
indicated that they would be interested in repackaging once their manufacturing plant is completed 
in about 18 months where they will then have the facilities to do so.   
Among local manufacturers who also engaged in importing of antimalarials, responses were varied.  
One local manufacturer who produced a full range of oral antimalarials also imported injectable 
antimalarials as there were no manufacturing facilities for injections in Nigeria.  These imported 
products arrived as finished products.  When asked if they would consider repackaging, the 
respondent indicated that they prefer to import finished products as it would not be cost-effective 
for them to repackage or re-label because the labour and materials required are cheaper in the 
country where most of their imports originate.  In Nigeria, another barrier to expanding operations 
to include repackaging is the issue of unreliable electricity supply and the substantial cost of running 
generators. 
Another manufacturer interviewed that also imported antimalarials did engage in the repackaging of 
these ‘semi-packaged’ or ‘palletised’ imports.  They also noted that 85% of inputs used for packaging 
are imported, including the cardboard (although printing is done locally).  For the finishing of 
imported blistered ACTs, the rough cost of packaging constitutes 6-20% of the final price of the 
product, depending on the cost of imported inputs.  As this respondent is a large manufacturer, they 
already have fully operational packaging facilities and run their packaging lines 24 hours a day.  
Because of this and despite having to import most of the packaging material, the respondent felt 
that it is more cost-effective to repackage locally rather than import finished product. 
The Society for Family Health (SFH) was also interviewed for this topic because of their extensive 
experience with importing health products.  Presently, SFH repackages condoms and intrauterine 
devices (a non-pharmaceutical contraceptive), applies a safety seal to some other contraceptive 
products (pills and injections), and inserts literature into a variety of packaged products.  All 
packaging materials are sourced locally, except for the safety seals which are imported, and the 
repackaging operations take place in their Lagos central facilities.  As an NGO, SFH saves 5% on the 
products they import for repackaging as they are not required to pay VAT which allows them to offer 
competitive pricing and gives them an advantage in negotiations.  Consequently, the cost of 
repackaging and applying the safety seal only has a small impact on the final selling price of the 
product.  
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8. Concluding Remarks 
Analysis of the current antimalarial product market indicates the enormous potential for impact in 
increasing access to effective antimalarials through the private commercial sector in Nigeria by 
subsidising ACTs under the AMFm.  While generally welcoming the idea of such an intervention, 
respondents underscored the importance of understanding the structure and operation of the 
private commercial drug distribution system in order to ensure the successful implementation of the 
AMFm. 
Through discussions with individuals from both the public and private sectors, a number of key 
barriers were identified, ranging from poor product availability at the top of the distribution chain to 
poor consumer acceptance of the subsidised product at the opposite end of the chain, and also 
recommendations to address them, as summarised below: 
- Implement a major public promotion campaign for the subsidised product to sensitise the 
population to the availability of low-cost effective antimalarial treatment in both the public and 
private sectors, to reduce domestic demand for antimalarials purchased in the informal sector, 
and to attract patients to formal structures to purchase subsidised ACTs. 
 
- Ensure sustained top-level availability of the subsidised product to avoid price speculation 
associated with scarcity. 
 
- Strengthen regulatory capacity through improved funding and greater powers to enforce 
regulations to better prevent leakage of subsidised product to the informal sector, minimise 
prevalence of counterfeit products, and improve end-user product quality. 
 
- Engage appropriately with the influential domestic pharmaceutical manufacturing sector to 
minimise their opposition to the AMFm. 
 
- Leverage PPMVs and use appropriate incentives to improve widespread access to quality ACTs. 
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International Manufacturers 
 Located mainly in Western 
Europe, India and China 
 Transport to customers 
Domestic Manufacturers 
 140 registered (2008) 
 Produce full range of generic and 
branded generic antimalarials 
 Transport to depots 
 May also import some products (e.g. 
injectables) 
 Mark-up: 15-40% 
 Credit: offered to authorised distributors 
after qualifying period; terms 7-45 days 
Central & Regional Depots 
 Owned and operated by manufacturers and/or 
importers or by specialised logistics companies 
 Located mainly in Lagos & regional centres 
 Deliver to customers & customers collect State Government 
Central Medical Stores 
 receives supplies from 
federal CMS and also 
through tenders for 
state and local level 
facilities 
 2 states operate model 
where they wholesale 
to private sector 
Private Hospitals/Clinics 
 Located mainly in urban 
centres 
PPMVs 
 13 903 registered (2006) 
 Located both in urban and 
rural areas, often only 
medicine provider in rural 
 Many operate without 
registration 
 Lead time: same day to 
several weeks 
Retail Pharmacies 
 1526 registered (2008) 
 Located mainly in urban 
centres 
 Mark-up: 20-30% 
 Lead time: same day to 
several weeks 
Informal Market 
 Located mainly in urban 
centres, often as market stall 
 Customers mainly collect 
 Volumes may be comparable 
to formal supply chain 
 Retailing is also common 
 Horizontal trade occurs 
Federal & State Hospitals 
and Local Government 
Health Centres 
 purchases mainly 
through tenders 
 also ad hoc purchases 
for small quantities and 
specialised products 
Federal Government 
Central Medical Stores 
 purchases mainly 
through tenders 
 pooled purchases at 
federal and state level 
leakages from the 
public and private 
sectors and illegal 
imports 
Legend 
             = formal supply source 
             = informal supply source 
             = cross-sectoral trade 
Importers 
 286 registered (2008) 
 Located mainly in Lagos and Onitsha 
 Pick up from port of entry 
 Mark-up: depends on cost of products 
and importing, exchange rate and 
competition in market 
 Lead time: 1 to several months 
 Credit: offered to authorised 
distributors after qualifying period; 
terms 7-45 days 
  
Authorised Distributors & Wholesalers 
 616 registered (2008) 
 Located mainly in urban centres 
 Some wholesalers act as authorised distributors 
for suppliers after qualifying 
 Horizontal trade occurs at this level 
 Deliver to customers directly or through waybill, 
or customers collect 
 Mark-up: 1-3%; 5-10%, 15% if scarce 
 Lead time: same day to 1 week (depending on 
location of depot) 
 Credit: may be offered to reliable customers (esp. 
if credit given by suppliers); terms 1-3 weeks 
Appendix 1: The private for-profit sector supply chain for antimalarials 
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Appendix 2: Population data used to scale-up ACTwatch Outlet Survey Data to generate 
national estimates of retail provider numbers 
Stratum name Lower North South East 
South South 
Upper North South West 
Population of 19 sub-districts visited for the 
ACTwatch Outlet Survey  
239,305  250,447  248,101  253,563  
Total stratum population from 2006 census 24,854,886  33,808,676  59,670,684  21,669,296  
Adjustment factor to scale up Outlet Survey data 103.9 135.0 240.5 85.5 
 
Appendix 3: Antimalarial doses used to calculate adult equivalent treatment doses 
Drug  Treatment regimen 
Amodiaquine 9 X 200 mg or      11 X 153.1 mg 
Artemether 14 X 50 mg or      7 X 100 mg 
Artemether – 
Lumefantrine 
24 X 20 mg / 120 mg  or      12 X 40 mg / 480 mg 
Artemisinin –Napthoquine 8 X 125 mg / 50 mg  
Artesunate 14 X 50 mg or      7 X 100 mg 
Artesunate - Amodiaquine 12 X 50 mg + 12 X 153.1 mg or      6 X 100 mg + 12 X 270 mg 
Artesunate – Mefloquine 12 X 50 mg + 6 X 250 mg or      6 X 100 mg + 6 X 250 mg 
Artesunate – SP 3 X 200 mg + 3 X 500 mg/25 mg 
6 X 100 mg + 6 X 500 mg/25 mg 
or      3 X 200 mg/500 mg/25 mg 
or      6 X 200 mg/500 mg/25 mg 
Chloroquine 15 X 100 mg or      10 X 150 mg 
DHA – Piperaquine 8 X 40 mg/320 mg or      12 X 30 mg/225mg 
DHA – SP 3 X  
Halofantrine 6 X 233 mg  
Quinine 18 X 100 mg or      6 X 300 mg 
SP 3 X 500 mg/25 mg  
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Appendix 4: Lists of registered artemisinin-based antimalarials in Nigeria 
PRODUCT NAME ACTIVE INGREDIENT NAME & ADDRESS OF 
APPLICANT 
NAME & ADDRESS OF 
MANUFACTURER 
PRESENTATION 
ACTIMAX ORAL 
SUSPENSION 
(RASPBERY,BANANA,OR  
ARTEMETHER 
15MG,LUMENFANTRINE 
90MG  
DIVINE ESSENTIAL 
FORMULATIONS KM 10, LASU 
OJO ROAD,  
SAME AS APPLICANT  SUSPENSION X 60ML  
ACTIMAX TABLETS (OTC)  ARTEMETHER 
40MG,LUMENFANTRINE 
240MG  
DIVINE ESSENTIALS 
FORMULATIONS KM 10,LASU 
OJO ROAD,EGAN  
SAME AS APPLICANT  TABLETS X 2 X 6'S  
ACTIVIN TABLETS (POM)  ARTESUNATE 
100MG,AMODIAQUINE 
300MG  
DIVINE ESSENTIALS 
FORMULATIONS KM 10,LASU 
OJO ROAD,EGAN  
SAME AS APPLICANT  TABLETS X 2 X 6'S  
ACTPRO AL TABLETS 
(OTC)  
ARTEMETHER 
20MG,LUMENFANTRINE 
120MG  
ECOMED PHARMA LTD. PLOT 
32, LYNSON CHEMICAL 
AVENUE, KM 38, LAGOS  
SAME AS APPLICANT  TABLETS X 24'S  
ACTPRO TABLETS (OTC)  ARTESUNATE  
50MG,AMODIAQUINE  
153MG  
ECOMED PHARMA LTD KM  
38,LAGOS-ABEOKUTA  
EXPRESSWAY,  
SAME AS APPLICANT  TABLETS X (12 +  
12)  
ARENAX ARTESUNATE X  
6'S  
ARTESUNATE 100MG  SWISS PHARMA NIG. LTD 5,  
DOPEMU RD., AGEGE, LAGOS  
SAME AS APPLICANT  TABLETS  
ARENAX PLUS TABLETS  
(OTC)  
ARTEMETHER  
20MG,LUMEFANTRINE  
120MG  
SWISS PHARMA LTD; 5,  
DOPEMU ROAD, AGEGE,  
LAGOS.  
ECOMED PHARMA LTD;  
PLOT 32, LYNSON  
CHEMICAL AVENUE, KM.  
TABLETS X 2 X  
14'S  
ARNET TABLETS (POM)  SODIUM ARTESUNATE,  
50MG  
VITAPHOS LAB (H) LTD 3,  
ADEDOTUN DINA  
CRESCENT, MARYLAND,  
SAME AS APPLICANT  TABLETS X 12'S  
ARTELUM TABLETS  ARTEMETER 40MG,  
LUMEFANTRINE 240MG  
MAY & BAKER NIG LTD 3/5,  
SAPARA STREET, IKEJA  
INDUSTRIAL ESTATE, IKEJA,  
SAME AS APPLICANT  12  
ARTEMAX  ARTESUNATE 100MG  SWISS PHARMA NIG. LTD. 5,  
DOPEMU ROAD, AGEGE - 
LAGOS.  
SWISS PHARMA NIG.  
LTD. 5, DOPEMU ROAD,  
AGEGE - LAGOS.  
TABLETS  
COFETRAN TABLETS  
(OTC)  
ARTEMETHER  
20MG,LUMEFANTRINE  
120MG  
CHAN MEDI PHARM LTD.  
LITTLE RAYFIELD, JOS,  
PLATEAU STATE  
ECOMED PHARMA LTD.  
KM 38,  
LAGOS-ABEOKUTA  
TABLETS X 2 X  
12'S  
COTEMAL TABLETS  
(OTC)  
ARTEMETHER  
50MG,AMODIAQUINE  
153MG  
CHAN MEDI PHARM LTD.  
LITTLE RAYFIELD, JOS,  
PLATEAU STATE  
ECOMED PHARMA LTD.  
KM 38,  
LAGOS-ABEOKUTA  
TABLETS X 1 X  
24'S  
DART ARTESUNATE &  
AMODIAQUINE  
ARTESUNATE 200MG,  
AMODIAQUINE HCL 
780MG  
SWISS PHARMA NIG LTD, 5,  
DOPEMU RD, AGEGE, LAGOS.  
SAME AS APPLICANT  TABLET  
DART TABLETS FOR  
CHILDREN (OTC)  
ARTESUNATE  
50MG,AMODIAQUINE 
HCL  
260MG  
SWISS PHARMA NIG. LTD  
5,DOPEMU RD, AGEGE,  
LAGOS  
SAME AS APPLICANT  6'S  
DART TABLETS FOR  
CHILDREN (OTC)  
ARTESUNATE  
50MG,AMODIAQUINE  
153MG  
SWISS PHARMA NIG. LTD.  
5, DOPEMU ROAD, AGEGE,  
LAGOS  
SAME AS APPLICANT  TABLETS X 6'S  
DIASUNATE CAPLETS  
(POM)  
ARTESUNATE 100MG +  
AMODIAQUINE 400MG  
EMZOR PHARM. IND. LTD.  
PLOT 3C, BLK A, ASWANI  
MARKET RD, ISOLO LAGOS  
SAME AS APPLICANT  CAPLETS X 6'S  
EFONREX DS CAPSULES  
(OTC)  
ARTESUNATE 100MG,  
AMODIAQUINE 400MG  
BOND CHEMICAL INDUSTRY  
LTD; ADESAKIN  
LAYOUT,OFF IWO  
SAME AS APPLICANT  CAPSULES X 6'S  
EFONREX TABLETS  
(OTC)  
ARTESUNATE 50MG  
AMODAQUINE 153.8MG  
BOND CHEMICAL IND. LTD  
ADESAKIN LAYOUT, AWE,  
OYO STATE, NIGERIA.  
SAME AS APPLICANT  TABLETS X 24  
FARENAX  
TABLET(FORMERLY  
FANSUNATE) (OTC)  
ARTESUNATE 200MG  
SULPHADOXINE 500MG  
PYRIMETHAMINE  
SWISS PHARMA NIG. LTD  
5,DOPEMU RD,AGEGE,LAGOS  
SAME AS APPLICANT  6'S  
FARENAX TABLETS FOR  
CHILDREN (OTC)  
ARTESUNATE  
50MG,SULPHADOXINE  
500MG,PYRIMETHAMINE 
25MG  
SWISS PHARMA NIG. LTD  
5,DOPEMU RD, AGEGE,  
LAGOS  
SAME AS APPLICANT  4'S  
GENOMSUNATE  
CAPSULES (OTC)  
ARTESUNATE  
50MG,AMODIAQUINE  
200MG  
GENOM PHARMACEUTICALS  
LTD. LAGOS-ABEOKUTA  
EXPRESSWAY, TOLLGATE  
SAME AS APPLICANT  CAPSULES X  
12'S  
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LA-TESEN DROPS (OTC)  ARTEMETHER  
20MG/ML,LUMEFANTRIN
E  
120MG/ML  
AFRAB-CHEM LTD.  
22, ABIMBOLA STREET,  
ISOLO IND. ESTATE, ISOLO,  
SAME AS APPLICANT  DROPS X 8ML  
LA-TESEN SUSPENSION  
(OTC)  
ARTEMETHER  
20MG/5ML,LUMEFANTRI
NE  
120MG/5ML  
AFRAB-CHEM LTD.  
22, ABIMBOLA STREET,  
ISOLO IND. ESTATE, ISOLO,  
SAME AS APPLICANT  SUSPENSION X  
60ML  
LUMETHER PAEDIATRIC  
DISPERSIBLE TABLETS  
(OTC)  
ARTEMETHER 10MG,  
LUMEFANTRINE 60MG  
VITAPHOS LAB. NIG. LTD; 3,  
ADEDOTUN DINA  
CRESCENT, MARYLAND,  
SAME AS APPLICANT  TABLETS X 24'S  
LUMETHER TABLETS  
(OTC)  
ARTEMETHER  
20MG,LUMENFANTRINE  
120MG  
VITAPHOS LAB. LTD. 3,  
ADEDOTUN DINA  
CRESCENT, MARYLAND,  
SAME AS APPLICANT  TABLETS X 2 X  
12'S  
LYNSUNATE TABLETS  
(OTC)  
ARTEMETHER  
20MG,LUMEFANTRINE  
120MG  
LYN-EDGE PHARM. LTD. NO.  
113 OLD ABA RD, PORT  
HARCOURT, RIVER STATE.  
SAME AS APPLICANT  TABLETS X 2 X  
12  
MALACT TABLETS (OTC)  ARTESUNATE  
100MG,AMODIAQUINE  
HYDROCHLORIDE 400MG  
MAY & BAKER NIG PLC. 3/5  
SAPARA STREET, IKEJA  
INDUSTRIAL ESTATE IKEJA  
SAME AS APPLICANT  TABLETS X 6 X  
6'S  
QINGHAO CAPSULES  
(POM)  
ARTEMISININ  
50MG,PIPERAQUINE  
PHOSPHATE 150MG  
FIDSON HEALTHCARE PLC;  
KM. 38, LAGOS – ABEOKUTA  
EXPRESSWAY, OTA, OGUN  
SAME AS APPLICANT  CAPSULES X  
10'S  
QUINARNET TABLETS  
(OTC)  
ARTESUNATE  
50MG,AMODIAQUINE  
200MG  
THERAPEUTICS LAB.LTD.  
372, IKORODU ROAD,  
MARYLAND, IKEJA, LAGOS  
VITAPHOS LAB. LTD. 3,  
ADEDOTUN DINA  
CRESCENT, MARYLAND,  
TABLETS X 12'S  
TEMECXIN TABS  DIHYDROARTEMISININ  
60MG  
BOND CHEMICALS IND LTD  
ADESAKIN LAYOUT, AWE  
SAME AS APPLICANT  8'S  
THERAMETHER  
SUSPENSION (POM)  
ARTEMETHER 15MG/ML  THERAPEUTIC LABS NIG.  
LTD. 372,IKORODU RD.,  
MARYLAND  
SAME AS APPLICANT  100ML  
VAMI'S ARTESUNATE  
TABLETS(POM)  
ARTESUNATE 50MG  TUYIL PHARM. IND LTD  
22,STADIU RD., ILORIN  
SAME AS APPLICANT  12'S  
WAIPA TABLETS (OTC)  DIHYDROARTEMISININ  
30MG, PIPERAQUINE  
PHOSPHATE 25M  
KUNIMED PHARMACHEM  
LTD. 1, ADELANWA ST.,  
VALLEY EST., DOPEMU  
SAME AS APPLICANT  12'S  
 
